pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

645 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1605Endpoints1257BioSpace587Fierce Biotech585BioPharma Dive474raps199onclive165fda recalls105fda medwatch
therapy area
allOncology10896Rare Disease2804Immunology2568Cardiology2302Pulmonology1918Hematology1912Vaccines1659Psychiatry & CNS1111
  • HHS vaccine committee receives new charter amid broader health policy updates
    The U.S. Health and Human Services vaccine advisory panel has been granted a new charter, a change that was noted quietly in a recent health newsletter. The same briefing highlighted other policy…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Physician blames U.S. health insurance failures after husband's suicide
    Joy Evers, an emergency physician, recounts the death of her husband Randy by suicide, describing how she expected her family’s high-quality commercial health insurance to ensure he received timely…
    STAT · 3mo agoNegative↗ source
← prev
page 19 of 26
next →
95
globenewswire health73
fda press55
Ophthalmology883
Endocrinology & Metabolism699
Pain678
Nephrology676
  • U.S. Military's New Testosterone Screening Raises Health Concerns
    The Department of Defense announced a mandatory testosterone screening program for all service members, prompting discussion among medical experts. A urologist who studies men’s health cautions th…
    STAT · 3mo agoNegative↗ source
  • STAT invites reader letters on primary care value, obesity as disease and broader health-care debates
    STAT’s First Opinion platform encourages readers to submit letters responding to its essays, fostering open, good‑faith discussion about health‑care topics. Recent letters, echoing comments from t…
    STAT · 3mo agoNeutral↗ source
  • FDA approves Lipfendra, first oral PCSK9 inhibitor, to lower LDL cholesterol in adults
    The U.S. Food and Drug Administration has approved Lipfendra (enlicitide), the first oral inhibitor of the PCSK9 protein, for use as an adjunct to diet and exercise in adults with high cholesterol,…
    fda press · 3mo agoApprovalPositive↗ source
  • Abbott Beats Q2 Expectations with Strong Device and Diagnostic Sales, Raises Profit Forecast
    Abbott reported second‑quarter results that exceeded analysts' forecasts, easing concerns about potential impact of ACA subsidy cuts on medtech firms. Diagnostics revenue jumped 42% year‑over‑year…
    Fierce Biotech · 3mo agoEarningsPositive↗ source
  • GSK drops chronic cough drug camlipixant after mixed Phase 3 results
    GSK announced it will stop investing in camlipixant for refractory chronic cough after the drug failed to meet key endpoints in a late-stage trial. The company had run two Phase 3 studies, CALM-1…
    BioSpace · 3mo agoNegative readoutNegative↗ source
  • Insmed's inhaled PAH therapy shows durable efficacy in 12-month extension, bolstering $6B sales outlook
    Insmed reported that its inhalable prostanoid candidate, treprostinil palmitil inhalation powder (TPIP), maintained functional and biomarker benefits through a 12‑month open‑label extension in pati…
    BioSpace · 3mo agoPositive readoutPositive↗ source
  • Biotronik Neuro acquires Soin Neuroscience spinal cord stimulation patent portfolio to boost next-gen pain therapy
    Biotronik Neuro, the neuromodulation arm of Berlin-based medtech firm Biotronik, announced it has purchased a collection of spinal cord stimulation patents from Ohio-based Soin Neuroscience. The a…
    Fierce Biotech · 3mo agoDealPositive↗ source
  • Canadian wildfires drive NYC asthma ER visits up 31% as heat wave intensifies haze
    Recent Canadian wildfires have produced massive smoke plumes that have drifted into the United States, degrading air quality across many cities. In New York City, emergency department visits for a…
    STAT · 3mo agoNeutral↗ source
  • Eli Lilly to buy psychedelics biotech AtaiBeckley for $2.8 billion, adding late-stage depression drug
    Eli Lilly announced it will acquire New York‑based biotech AtaiBeckley in a transaction valued at about $2.8 billion. The agreement sets the purchase price at $6.75 per share, a 26 % premium to At…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Merck wins FDA nod for first oral PCSK9 inhibitor, Lipfendra, to treat high LDL cholesterol
    Merck announced that the U.S. Food and Drug Administration has approved its once-daily oral PCSK9 inhibitor, enlicitide, marketed as Lipfendra, for adults with elevated LDL cholesterol. The drug i…
    BioSpace · 3mo agoApprovalPositive↗ source
  • Medicare proposes overhaul of payment models for clinical AI and remote patient monitoring
    The Centers for Medicare and Medicaid Services (CMS) has announced a set of proposals aimed at reshaping how Medicare reimburses clinical artificial intelligence tools and remote patient monitoring…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Three biotech firms launch IPOs to challenge giants in cardiometabolic and immunology markets
    Braveheart Bio, Attovia Therapeutics and Vogenx filed for initial public offerings this week, adding to a surge of biotech listings in 2026. Braveheart is developing a therapy for hypertrophic car…
    BioSpace · 3mo agoDealNeutral↗ source
  • Kalshi to Offer Prediction Market Bets on Clinical Trials and Regulatory Approvals
    Kalshi, one of the world’s largest prediction‑market exchanges, announced it will start allowing bets on the outcomes of clinical trials and regulatory approvals. The initiative could give investor…
    STAT · 3mo agoNeutral↗ source
  • Venom’s hidden potential fuels next wave of peptide medicines beyond GLP-1 weight-loss drugs
    Steve Midway, an associate professor at LSU, argues that many powerful medicines already exist in the venoms of feared creatures, noting that venom contributed to the development of GLP-1 based wei…
    STAT · 3mo agoPositive↗ source
  • ADA blocks Diabetes Care editorial on conference controversy, sparking fresh turmoil
    Turmoil at the American Diabetes Association (ADA) has intensified after leaders prevented editors of its flagship journal, Diabetes Care, from publishing an editorial and first-person accounts abo…
    STAT · 3mo agoNegative↗ source
  • Senator Lindsey Graham’s death highlights gaps in detecting aortic dissection
    Senator Lindsey Graham, 71, died on Saturday after suffering an aortic dissection, a sudden tear in the body's main blood vessel that can be fatal. A final death certificate has not yet been relea…
    STAT · 3mo agoNegative↗ source
  • Braveheart Bio seeks Nasdaq listing to finance Phase 3 trial of Hengrui rival cardio drug
    Braveheart Bio announced it has filed for an initial public offering on the Nasdaq exchange. The company says the capital raised will be used to fund a Phase 3 study of its cardiovascular candidate…
    Endpoints · 3mo agoNeutral↗ source
  • Attovia Therapeutics and Braveheart Bio announce plans for biotech IPOs amid market upswing
    Attovia Therapeutics and Braveheart Bio disclosed on Tuesday that they intend to go public, joining a recent wave of large biotech offerings. Attovia, which was spun out of Alamar Biosciences in 2…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Coronary artery disease deaths in US have halved since 1990, but most recent deaths remain preventable
    A new analysis published in JAMA Cardiology shows that deaths from ischemic heart disease in the United States dropped by more than half between 1990 and 2023. The decline is attributed to improved…
    STAT · 3mo agoPositive↗ source
  • Uncertainty persists over food source of summer cyclospora outbreak, officials say
    A parasite called cyclospora has infected nearly 7,000 people across 34 states this summer, marking one of the largest surges on record. Michigan health officials have identified lettuce and salad…
    STAT · 3mo agoNegative↗ source
  • Senator Lindsey Graham's death from aortic dissection spotlights need for better screening
    Senator Lindsey Graham died at age 71 after suffering an aortic dissection, drawing public attention to this rare but deadly condition. An aortic dissection occurs when the body's main blood vesse…
    STAT · 3mo agoNegative↗ source
  • 340B Drug Discount Program sales hit $100 billion in 2025, up 22.8% year over year
    The Health Resources and Services Administration reported that purchases under the 340B discount program reached $100 billion in 2025, a 22.8% rise from 2024. Expensive medicines made up a growing…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Former FDA toxicologist says agency approved Zyn nicotine pouches without fully knowing their composition
    Former FDA toxicologist Christy Leppanen alleges the agency authorized Zyn nicotine pouches without complete safety data on the pouch material. Leppanen, who led a microplastics exposure project a…
    STAT · 3mo agoRegulatoryNegative↗ source